Cancer Vaccine Makers Capitalize On Provenge Fanfare At ASCO
Executive Summary
Heading into this year's American Society of Clinical Oncology meeting, beleaguered cancer immunotherapy developers finally have some cause for optimism about potential partnerships and, battle-hardened, they say they are hearty enough to wait for deals to roll in
You may also be interested in...
Takeda May Resurrect IDM’s Bone Cancer Drug Mifamurtide In U.S.
Fate of IDM’s dendritic cell-based Uvidem and other cancer vaccines remains unclear after $75 million purchase.
GlobeImmune Gets A Shot In The Arm Thanks To Celgene Cancer Collaboration
Hepatitis C vaccine success validated technology and paved way for the deal.
ASCO Abstracts Hold Some Surprises Including Data On AZ’s Vandetanib, Bristol’s Ipilimumab
Despite the lack of innovative drugs highlighted in ASCO's media briefing on its upcoming annual meeting, there is a range of oncology development updates that will be presented - including some surprises